Novel circulating tumor cell-based blood test for the assessment of PD-L1 protein expression in treatment-naïve, newly diagnosed patients with non-small cell lung cancer

Yen Lin Chen, Wen Chien Huang, Feng Ming Lin, Huangpin B. Hsieh, Chia Hsun Hsieh, Ruey Kuen Hsieh, Kuo Wei Chen, Ming Hong Yen, James Lee, Stephen Su, Twinkal Marfatia, Shih En Chang, Padma Sundar, Bruce Patterson, Drew Watson, Rui Mei, Manana Javey*

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

21 Scopus citations

Abstract

We evaluated the analytical and clinical performance of a novel circulating tumor cell (CTC)-based blood test for determination of programmed death ligand 1 (PD-L1) protein expression status in real time in treatment-naïve non-small cell lung cancer (NSCLC) patients. CTCs were detected in 86% of patients with NSCLC (I–IV) at the time of diagnosis, with a 67% PD-L1 positivity rate (≥ 1 PDL + CTC). Among 33 NSCLC patients with PD-L1 results available via both tissue immunohistochemistry (IHC) and CTC assays, 78.9% were positive according to both methods. The CTC test identified an additional ten cases that were positive for PD-L1 expression but that tested negative via IHC analysis. Detection of higher PD-L1 expression on CTCs compared to that in the corresponding tissue was concordant with data obtained using other platforms in previously treated patients. The concordance in PD-L1 expression between tissue and CTCs was approximately 57%, which is higher than that reported by others. In summary, evaluation of PD-L1 protein expression status on CTCs isolated from NSCLC patients is feasible. PD-L1 expression status on CTCs can be determined serially during the disease course, thus overcoming the myriad challenges associated with tissue analysis.

Original languageEnglish
Pages (from-to)1087-1094
Number of pages8
JournalCancer Immunology Immunotherapy
Volume68
Issue number7
DOIs
StatePublished - 01 07 2019
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2019, The Author(s).

Keywords

  • Checkpoint inhibitor therapy
  • Circulating tumor cells
  • Liquid biopsy
  • Non-small cell lung cancer
  • PD-L1 expression

Fingerprint

Dive into the research topics of 'Novel circulating tumor cell-based blood test for the assessment of PD-L1 protein expression in treatment-naïve, newly diagnosed patients with non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this